Site icon Todd K Marsha

Trump Announces U.S. Drug Pricing Deal With AstraZeneca

Trump Announces U.S. Drug Pricing Deal With AstraZeneca

<p><&excl;-- BEGIN THEIA POST SLIDER --><&sol;p>&NewLine;<p> <br &sol;>&NewLine;<&sol;p>&NewLine;<div style&equals;"position&colon;relative">&NewLine;<p>President Donald Trump unveiled a deal with U&period;K&period;-based drugmaker AstraZeneca on Friday under which the company will sell some medicines at a discount to the government’s Medicaid health plan in exchange for tariff relief&comma; similar to a drug pricing pact reached last week with Pfizer&period;<&sol;p>&NewLine;<p>The deals set a framework the White House will use to try to reach its goal of lowering U&period;S&period; prescription medicine prices&period; The president sent letters to 17 leading drugmakers in July telling them to slash prices&period; Pfizer and Astra are the first two companies to reach a deal with the administration&period;<&sol;p>&NewLine;<p>AstraZeneca will also offer some of its drugs at up to 80&percnt; off their list price through the TrumpRx website planned for next year&comma; CEO Pascal Soriot said at an event in the Oval Office&period;<&sol;p>&NewLine;<p>He said the company will receive a three-year tariff exemption &OpenCurlyDoubleQuote;to localize the remainder of our products&period;”<&sol;p>&NewLine;<p>U&period;S&period; patients currently pay by far the most for prescription medicines&comma; often nearly three times more than in other developed nations&comma; and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere or face stiff tariffs&period;<&sol;p>&NewLine;<p>Last month&comma; Trump threatened 100&percnt; tariffs&comma; ratcheting up pressure on the pharmaceutical industry to agree to price cuts and shift manufacturing to the U&period;S&period;&comma; after negotiations broke down earlier this year&comma; lobbyists and executives told Reuters following the Pfizer deal&period;<&sol;p>&NewLine;<p>More than 70 million people are covered by Medicaid&comma; the state and federal government program for low-income people&period; Drug spending in that program is dwarfed by that of Medicare&comma; which covers people aged 65 and older or those with disabilities and is not included in Friday’s announcement&period;<&sol;p>&NewLine;<p><strong><a href&equals;"https&colon;&sol;&sol;get&period;dailywire&period;com&sol;subscribe&sol;plus&sol;&quest;utm&lowbar;campaign&equals;fall40&amp&semi;utm&lowbar;content&equals;fallsale&amp&semi;utm&lowbar;medium&equals;website&amp&semi;utm&lowbar;source&equals;editorial" target&equals;"&lowbar;blank" rel&equals;"noopener">Get 40&percnt; off new DailyWire&plus; annual memberships with code FALL40 at checkout<&sol;a><&sol;strong><&sol;p>&NewLine;<p>Medicare’s drug spending reached &dollar;216 billion in 2021&comma; while Medicaid’s gross spending was around &dollar;80 billion&period;<&sol;p>&NewLine;<p>The Medicaid program already receives the lowest drug prices in the U&period;S&period;&comma; so the additional savings may be modest&comma; said Craig Garthwaite&comma; a professor at Northwestern University’s Kellogg School of Management&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;If you look at AstraZeneca’s portfolio&comma; I don’t think there are a bunch of drugs that exist where that’s going to involve them giving a very big discount to Medicaid&comma;” Garthwaite said&period;<&sol;p>&NewLine;<p>AstraZeneca’s Pfizer‑like deal may spare it tariffs&comma; but will not move the needle on U&period;S&period; rising health insurance premiums and out‑of‑pocket drug costs&comma; said Rena Conti&comma; an associate professor at Boston University&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;It’s good for the companies&comma; and has very uncertain if any benefit for Americans struggling with the affordability of prescription drugs&comma;” Conti said&period;<&sol;p>&NewLine;<p>Soriot has worked to keep his company close to Washington while pursuing its growth strategy&period;<&sol;p>&NewLine;<p>AstraZeneca in July announced it will invest &dollar;50 billion in U&period;S&period; manufacturing and research and development by 2030&period; It will build its biggest site worldwide in Virginia&comma; and expand facilities in five other U&period;S&period; states&period;<&sol;p>&NewLine;<p>In September&comma; the company announced it will sell its diabetes and asthma drugs direct to cash-paying U&period;S&period; patients at a discount of up to 70&percnt; off list prices&comma; another move in response to Trump’s pressure campaign&period;<&sol;p>&NewLine;<p>Soriot this year has played up the company’s U&period;S&period; credentials&period; He described the Anglo-Swedish firm as a &OpenCurlyDoubleQuote;very American company&comma;” highlighting its identity shift toward its largest market&period; AstraZeneca will list its shares in the United States as well as its current markets in the UK and Europe&period;<&sol;p>&NewLine;<p>&lpar;Reporting by Steve Holland in Washington and Michael Erman in New Jersey&semi; Additional reporting by Jarrett Renshaw and Ahmed Aboulenein in Washington&comma; Maggie Fick in London&comma; Patrick Wingrove in New York and Mariam E Sunny in Bengaluru&semi; Editing by Caroline Humer and Bill Berkrot&rpar;<&sol;p>&NewLine;<&sol;div>&NewLine;<p><br &sol;>&NewLine;<br &sol;><a href&equals;"https&colon;&sol;&sol;www&period;dailywire&period;com&sol;news&sol;trump-announces-u-s-drug-pricing-deal-with-astrazeneca">Source link <&sol;a><&sol;p>&NewLine;<p><&excl;-- END THEIA POST SLIDER --><&sol;p>&NewLine;

Exit mobile version